About OpGen
OpGen is a company based in Rockville (United States) founded in 2002.. OpGen has raised $77.51 million across 19 funding rounds from investors including European Union, 180 Degree Capital and Merck Global Health Innovation Fund. The company has 4 employees as of December 31, 2024. OpGen has completed 1 acquisition, including Curetis. OpGen offers products and services including Molecular Microbiology Services and CapForce Fintech Arm. OpGen operates in a competitive market with competitors including Prenetics, Karius, Day Zero Diagnostics, Clear Labs and Spring Bank Pharmaceuticals, among others.
- Headquarter Rockville, United States
- Employees 4 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Opgen, Inc.
-
Annual Revenue
$5.2 M52.01as on Dec 31, 2024
-
Net Profit
$11.99 M136.7as on Dec 31, 2024
-
EBITDA
$574.63 K104as on Dec 31, 2024
-
Total Equity Funding
$77.51 M (USD)
in 19 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Feb 24, 2021
-
Investors
European Union
& 12 more
-
Employee Count
4
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OpGen
OpGen is a publicly listed company on the OTC with ticker symbol OPGN in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OpGen
OpGen offers a comprehensive portfolio of products and services, including Molecular Microbiology Services and CapForce Fintech Arm. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Offers solutions to combat antimicrobial resistance using advanced techniques.
Provides financial technology solutions as a new business expansion.
Unlock access to complete
Unlock access to complete
Funding Insights of OpGen
OpGen has successfully raised a total of $77.51M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Post-IPO — $25.0M
-
First Round
First Round
(24 Jan 2005)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Post-IPO - OpGen | Valuation |
investors |
|
| Dec, 2020 | Amount | Post-IPO - OpGen | Valuation |
investors |
|
| Jul, 2018 | Amount | Post-IPO - OpGen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OpGen
OpGen has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, 180 Degree Capital and Merck Global Health Innovation Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital is focused on the life science sector.
|
Founded Year | Domain | Location | |
|
Venture capital investment and entrepreneur support services.
|
Founded Year | Domain | Location | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OpGen
OpGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Curetis. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics platform is provided for infectious disease detection.
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - OpGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Opgen Comparisons
Competitors of OpGen
OpGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prenetics, Karius, Day Zero Diagnostics, Clear Labs and Spring Bank Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
|
| domain | founded_year | HQ Location |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| domain | founded_year | HQ Location |
Genome sequencing diagnostics for infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Food safety technologies are provided for pathogen identification.
|
|
| domain | founded_year | HQ Location |
Viral infection treatments are developed using nucleic acid hybrid chemistry.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Opgen
Frequently Asked Questions about OpGen
When was OpGen founded?
OpGen was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Where is OpGen located?
OpGen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Who is the current CEO of OpGen?
Oliver Schacht is the current CEO of OpGen.
Is OpGen a funded company?
OpGen is a funded company, having raised a total of $77.51M across 19 funding rounds to date. The company's 1st funding round was a Post-IPO of $285.51K, raised on Jan 24, 2005.
How many employees does OpGen have?
As of Dec 31, 2024, the latest employee count at OpGen is 4.
What is the annual revenue of OpGen?
Annual revenue of OpGen is $5.2M as on Dec 31, 2024.
What does OpGen do?
Founded in 2002 and headquartered in Rockville, United States, OpGen operates in the diagnostics and bioinformatics sector. Platforms and tests, including the Acuitas MDRO Gene Test, Acuitas Lighthouse MDRO Management System, and Acuitas Resistome Test, are provided to healthcare providers. These tools support the detection of multi-drug resistant organisms in hospital patients, aiding infection management efforts.
Who are the top competitors of OpGen?
OpGen's top competitors include Prenetics, Clear Labs and Day Zero Diagnostics.
What products or services does OpGen offer?
OpGen offers Molecular Microbiology Services and CapForce Fintech Arm.
Is OpGen publicly traded?
Yes, OpGen is publicly traded on OTC under the ticker symbol OPGN.
How many acquisitions has OpGen made?
OpGen has made 1 acquisition, including Curetis.
Who are OpGen's investors?
OpGen has 13 investors. Key investors include European Union, 180 Degree Capital, Merck Global Health Innovation Fund, Highland Capital Partners, and Versant Ventures.
What is OpGen's ticker symbol?
The ticker symbol of OpGen is OPGN on OTC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.